An International Phase 3, Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

ID Number 13-0476

Principal Investigator(s)
Michael A Palese

Department(s) or Division(s)


This research study is evaluating an experimental (investigational) drug called AGS-003 to see if it is effective against kidney cancer. An experimental drug has not been approved for use in the general population by the United States Food and Drug Administration (FDA). AGS-003 is made for you by using a piece of tumor collected after surgical removal of your kidney along with a certain type of your own white blood cells. The resulting product is a type of immune cell called a dendritic cell. It is not known if the AGS-003 made dendritic cell will work the same way as natural dendritic cells.

AGS-003 can be used in combination with the approved, regular medications most often prescribed for the treatment of kidney cancer. In this study, one group of subjects will receive regular medications for kidney cancer and a second group will receive regular medications for kidney cancer plus AGS-003. The purpose of this study is to see if AGS-003 plus regular medications is any different than treatment with regular medications alone.

Contact Information
Lourdes Campos-Grundvig
(212) 824-7877

Recruiting Patients: No